Reference Intervals for Bone Turnover Markers in Korean Healthy Women

Overview

Journal J Bone Metab

Date 2020 Mar 20

PMID 32190608

Citations 7

Authors

Dong Hyeok Cho

Jin Ook Chung

Min Young Chung

Jeong-Ran Cho

Dong Jin Chung

Affiliations

Soon will be listed here.

Abstract

Background: Adequate suppression of bone turnover rate is important to decrease fracture risk without mineralization defect due to oversuppression. This study was performed to determine reference intervals (RIs) for 2 bone turnover markers, serum C-terminal telopeptide of type I collagen (CTX) and osteocalcin, in Korean women.

Methods: A total of 461 Korean women (287 premenopausal and 174 postmenopausal) without any disease or drug history affecting bone metabolism was included. Serum CTX and osteocalcin were measured after overnight fasting. Bone mineral density (BMD) was measured at the 1st to 4th lumbar vertebra using dual energy X-ray absorptiometry. Subjects with normal spinal BMD (T-score ≥-1.0) were included in this study.

Results: After stable concentrations were maintained, both CTX and osteocalcin were abruptly increased in 50 to 59 years, and then decreased with increasing age. Median levels and interquartile range of serum CTX and osteocalcin in all subjects were 0.322 (0.212-0.461) ng/mL and 15.68 (11.38-19.91) ng/mL. RIs for serum CTX and osteocalcin in all subjects were 0.115 to 0.861 ng/mL and 6.46 to 36.76 ng/mL. Those were higher in postmenopausal women (CTX, 0.124-1.020 ng/mL, osteocalcin, 5.42-41.57 ng/mL) than in premenopausal women (CTX, 0.101-0.632 ng/mL, osteocalcin, 6.73-24.27 ng/mL). If we use target reference levels as lower half of premenopausal 30 to 45 years in patients with antiresorptive drugs, those were 0.101 to 0.251 ng/mL and 6.40 to 13.36 ng/mL.

Conclusions: We established RIs for serum CTX and osteocalcin in healthy Korean women with normal lumbar spine BMD. Premenopausal RIs for serum CTX and osteocalcin would be useful to monitor patients with low bone mass using osteoporosis drugs.

Citing Articles

Comparison of bone turnover suppression in atypical femoral fractures and osteoporotic hip fractures.

Ahn J, Kim C, Kim J Sci Rep. 2024; 14(1):19974.

PMID: 39198602 PMC: 11358450. DOI: 10.1038/s41598-024-71024-y.

Effectiveness and Usefulness of Bone Turnover Marker in Osteoporosis Patients: A Multicenter Study in Korea.

Yoo J, Park S, Kim D, Ha J, Rhee Y, Hong N J Bone Metab. 2023; 30(4):311-317.

PMID: 38073264 PMC: 10721375. DOI: 10.11005/jbm.2023.30.4.311.

The Use of Bone-Turnover Markers in Asia-Pacific Populations.

Vasikaran S, Thambiah S, Tan R, Loh T Ann Lab Med. 2023; 44(2):126-134.

PMID: 37869778 PMC: 10628755. DOI: 10.3343/alm.2023.0214.

Bone Turnover Markers: Basic Biology to Clinical Applications.

Schini M, Vilaca T, Gossiel F, Salam S, Eastell R Endocr Rev. 2022; 44(3):417-473.

PMID: 36510335 PMC: 10166271. DOI: 10.1210/endrev/bnac031.

Nair S, Hatkar S, Patil A, Surve S, Joshi B, Balasinor N Arch Osteoporos. 2021; 16(1):146.

PMID: 34606009 DOI: 10.1007/s11657-021-01014-4.

References

de Papp A, Bone H, Caulfield M, Kagan R, Buinewicz A, Chen E . A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone. 2007; 40(5):1222-30. DOI: 10.1016/j.bone.2007.01.008. View

Bell N, Greene A, Epstein S, Oexmann M, Shaw S, Shary J . Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest. 1985; 76(2):470-3. PMC: 423843. DOI: 10.1172/JCI111995. View

Eastell R, Barton I, Hannon R, Chines A, Garnero P, Delmas P . Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003; 18(6):1051-6. DOI: 10.1359/jbmr.2003.18.6.1051. View

Aloia J, Mikhail M, Pagan C, Arunachalam A, Yeh J, Flaster E . Biochemical and hormonal variables in black and white women matched for age and weight. J Lab Clin Med. 1998; 132(5):383-9. DOI: 10.1016/s0022-2143(98)90109-3. View

Johansson H, Oden A, Kanis J, McCloskey E, Morris H, Cooper C . A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int. 2014; 94(5):560-7. DOI: 10.1007/s00223-014-9842-y. View

Gertz B, Shao P, HANSON D, Quan H, Harris S, Genant H . Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res. 1994; 9(2):135-42. DOI: 10.1002/jbmr.5650090202. View

Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P . National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int. 2012; 23(10):2425-33. PMC: 4011662. DOI: 10.1007/s00198-012-2049-z. View

Park S, Ahn S, Yoo J, Chung Y, Jeon Y, Yoon B . Clinical Application of Bone Turnover Markers in Osteoporosis in Korea. J Bone Metab. 2019; 26(1):19-24. PMC: 6416153. DOI: 10.11005/jbm.2019.26.1.19. View

Glendenning P . Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards: osteoporos int 2011;22:391-420. Clin Biochem Rev. 2011; 32(1):45-7. PMC: 3052393. View

10.

Recker R, Lappe J, Davies K, Heaney R . Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res. 2004; 19(10):1628-33. DOI: 10.1359/JBMR.040710. View

11.

Iki M, Akiba T, Matsumoto T, Nishino H, Kagamimori S, Kagawa Y . Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int. 2004; 15(12):981-91. DOI: 10.1007/s00198-004-1634-1. View

12.

Garnero P, Sornay-Rendu E, CHAPUY M, Delmas P . Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996; 11(3):337-49. DOI: 10.1002/jbmr.5650110307. View

13.

Glover S, Garnero P, Naylor K, Rogers A, Eastell R . Establishing a reference range for bone turnover markers in young, healthy women. Bone. 2008; 42(4):623-30. DOI: 10.1016/j.bone.2007.12.218. View

14.

Hu W, Zhang Z, He J, Fu W, Wang C, Zhang H . Establishing reference intervals for bone turnover markers in the healthy shanghai population and the relationship with bone mineral density in postmenopausal women. Int J Endocrinol. 2013; 2013:513925. PMC: 3600195. DOI: 10.1155/2013/513925. View

15.

Adami S, Bianchi G, Brandi M, Giannini S, Ortolani S, DiMunno O . Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int. 2008; 82(5):341-7. DOI: 10.1007/s00223-008-9126-5. View

16.

Kleerekoper M, Nelson D, Peterson E, Flynn M, Pawluszka A, Jacobsen G . Reference data for bone mass, calciotropic hormones, and biochemical markers of bone remodeling in older (55-75) postmenopausal white and black women. J Bone Miner Res. 1994; 9(8):1267-76. DOI: 10.1002/jbmr.5650090817. View

17.

Glover S, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S . Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res. 2008; 24(3):389-97. DOI: 10.1359/jbmr.080703. View

18.

Garnero P, Shih W, Gineyts E, Karpf D, Delmas P . Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994; 79(6):1693-700. DOI: 10.1210/jcem.79.6.7989477. View

19.

Hoshino H, Kushida K, Takahashi M, Yamazaki K, Denda M, Atsumi K . Changes in levels of biochemical markers and ultrasound indices of Os calcis across the menopausal transition. Osteoporos Int. 2000; 11(2):128-33. DOI: 10.1007/s001980050016. View

20.

Gossiel F, Finigan J, Jacques R, Reid D, Felsenberg D, Roux C . Establishing reference intervals for bone turnover markers in healthy postmenopausal women in a nonfasting state. Bonekey Rep. 2014; 3:573. PMC: 4162466. DOI: 10.1038/bonekey.2014.68. View